Astragaloside IV Ameliorates Allergic Rhinitis Comorbid With Asthma by Inhibiting the Antigen‐Presenting Function of B Cells
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70247 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, 2026. Written by Ruizhi Wang and 8 co-authors. Institution: Department of Otolaryngology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Major MEDLINE topics: Asthma, Saponins, Triterpenes, Rhinitis, Allergic. Cited 1 times so far (Crossref); 41 references. Funded by: National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (original language)
Astragaloside IV (AST) is one of the main active components of Astragalus membranaceus (Fisch.) Bunge, possessing definite immunomodulatory properties. However, its efficacy and mechanism remain unclear in allergic rhinitis comorbid with asthma (ARCA). This study aims to investigate whether AST can improve ARCA by inhibiting antigen presentation. An ARCA mouse model was established to assess airway allergic symptoms; serum inflammatory factors were detected by ELISA, airway tissue pathology by HE, PAS and Masson staining and inflammatory factor expression, antigen‐presenting cell activation and JAK2/STAT1 pathway activity by WB, IHC and IF. AST improved airway allergic symptoms, downregulated the expression of OVA‐sIgE and IL‐4 and upregulated the expression of OVA‐sIgG. It also alleviated eosinophil infiltration, goblet cell metaplasia and collagen fibre proliferation and inhibited the expression of ECP, CD3e, CD4 and IL‐4 in airway tissues. The antigen‐presenting function of B cells in the airway tissues of ARCA mice was activated, while AST inhibited this function. Moreover, AST downregulated the expression of p‐JAK2, STAT1, p‐STAT1 and MHC II in airway tissues. In conclusion, B cells are the key effector cells mediating antigen presentation in the challenge phase of ARCA. AST can inhibit the antigen‐presenting function of B cells via regulating the JAK2/STAT1 signalling pathway, thereby alleviating the Th2‐type inflammatory response in ARCA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otolaryngology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of Allergy, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Key Laboratory of Airway Inflammatory Disease Research and Innovative Technology Translation, Guangzhou, China.
- Department of School of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, China.
- Department of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
ORCID profiles: Ruizhi Wang, Junhai Chen, Min Zhou
Funding
- National Key R&D Program of China
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Cite
APA
Wang, R., Chen, J., Ye, F., Li, Y., Chen, T., Dai, M., Zhang, K., Yang, Q., & Zhou, M. (2026). Astragaloside IV Ameliorates Allergic Rhinitis Comorbid With Asthma by Inhibiting the Antigen‐Presenting Function of B Cells. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70247
Vancouver
Wang R, Chen J, Ye F, Li Y, Chen T, Dai M, et al. Astragaloside IV Ameliorates Allergic Rhinitis Comorbid With Asthma by Inhibiting the Antigen‐Presenting Function of B Cells. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70247
BibTeX
@article{Wang2026,
author = {Wang, Ruizhi and Chen, Junhai and Ye, Fan and Li, Yiwen and Chen, Tianzhu and Dai, Min and Zhang, Kun and Yang, Qintai and Zhou, Min},
title = {Astragaloside IV Ameliorates Allergic Rhinitis Comorbid With Asthma by Inhibiting the Antigen‐Presenting Function of B Cells},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70247}
}
EUVIMED